Gilead Sciences Announces Third Quarter 2011 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the quarter ended September 30, 2011. Total revenues for the third quarter of 2011 were $2.12 billion, up 9 percent compared to total revenues of $1.94 billion for the third quarter of 2010. Net income for the third quarter of 2011 was $741.1 million, or $0.95 per diluted share, compared to net income for the third quarter of 2010 of $704.9 million, or $0.83 per diluted share. Non-GAAP net income for the third quarter of 2011, which excludes after-tax acquisition-related, restructuring and stock-based compensation expenses, was $795.2 million, or $1.02 per diluted share, compared to non-GAAP net income for the third quarter of 2010 of $759.7 million, or $0.90 per diluted share.

Product Sales

Product sales increased 11 percent to $2.07 billion for the third quarter of 2011, compared to $1.87 billion in the third quarter of 2010. This increase in sales was driven primarily by Gilead’s antiviral franchise, due to strong growth in sales of Atripla^® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and Truvada^® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg).

Antiviral Franchise

Antiviral product sales increased 9 percent to $1.79 billion in the third quarter of 2011, up from $1.65 billion for the same quarter of 2010.

• Atripla

Sales of Atripla for the treatment of HIV infection increased 7 percent to $794.7 million for the third quarter of 2011, up from $742.7 million in the third quarter of 2010, driven primarily by sales volume growth in Europe and the United States.

• Truvada

Sales of Truvada for the treatment of HIV infection increased 11 percent to $744.7 million for the third quarter of 2011, up from $668.7 million in the third quarter of 2010, driven primarily by sales volume growth in Europe and the United States.

• Viread

Sales of Viread^® (tenofovir disoproxil fumarate) for the treatment of HIV infection and chronic hepatitis B increased 5 percent to $192.9 million for the third quarter of 2011, up from $184.3 million in the third quarter of 2010. Sales increases in Europe and the United States were partially offset by lower sales in Latin America.

• Complera

Sales of our newest product, Complera^® (emtricitabine 200 mg/rilpilvirine 25 mg/tenofovir disoproxil fumarate 300 mg) for the treatment of HIV infection, were $19.0 million for the third quarter of 2011. On August 10, 2011, the U.S. Food and Drug Administration (FDA) approved Complera, a new once-daily, complete single-tablet HIV treatment regimen for treatment-naïve adults.

Letairis

Sales of Letairis^® (ambrisentan) for the treatment of pulmonary arterial hypertension increased 31 percent to $79.0 million for the third quarter of 2011, up from $60.4 million for the third quarter of 2010, driven primarily by sales volume growth.

Ranexa

Sales of Ranexa^® (ranolazine) for the treatment of chronic angina increased 36 percent to $82.0 million for the third quarter of 2011, up from $60.3 million for the third quarter of 2010, driven primarily by sales volume growth.

Other Products

Sales of other products were $153.6 million for the third quarter of 2011 compared to $149.1 million for the third quarter of 2010 and included AmBisome^® (amphotericin B) liposome for injection for the treatment of severe fungal infections, Hepsera^® (adefovir dipivoxil) for the treatment of chronic hepatitis B, Emtriva^® (emtricitabine) for the treatment of HIV infection and Cayston^® (aztreonam for inhalation solution) for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa (P. aeruginosa). Sales of Cayston were $23.6 million for the third quarter of 2011, up from $14.7 million in the same quarter of 2010 driven by sales volume growth in the United States.

Royalty, Contract and Other Revenues

Royalty, contract and other revenues from collaborations were $55.8 million in the third quarter of 2011, down 23 percent from $72.1 million in the third quarter of 2010. This decrease was due to an 89 percent decrease in Tamiflu royalties from F. Hoffmann-La Roche Ltd to $3.7 million in the third quarter of 2011 from $34.5 million in the third quarter of 2010, as pandemic planning initiatives worldwide have declined.

Research and Development

Research and development (R&D) expenses in the third quarter of 2011 were $290.1 million, compared to $230.4 million for the third quarter of 2010. Non-GAAP R&D expenses for the third quarter of 2011, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $269.3 million, compared to $203.2 million for the third quarter of 2010. The increase in non-GAAP R&D expenses was due primarily to increased clinical activities and expenses associated with acquisitions and collaborations.

Selling, General and Administrative

Selling, general and administrative (SG&A) expenses in the third quarter of 2011 were $295.9 million, compared to $250.6 million for the third quarter of 2010. Non-GAAP SG&A expenses for the third quarter of 2011, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $265.1 million, compared to $220.6 million for the third quarter of 2010. The increase in non-GAAP SG&A expenses was driven primarily by the impact of the pharmaceutical excise tax resulting from U.S. healthcare reform, expansion of commercial activities and legal expenses.

Net Foreign Currency Exchange Impact

The net foreign currency exchange impact on third quarter 2011 revenues and pre-tax earnings, which includes revenues and expenses generated from outside the United States, was a favorable $19.9 million and $2.6 million, respectively, compared to the third quarter of 2010.

Cash, Cash Equivalents and Marketable Securities

As of September 30, 2011, Gilead had cash, cash equivalents and marketable securities of $5.48 billion compared to $5.32 billion as of December 31, 2010. Gilead generated $2.66 billion of operating cash flow during the first nine months of 2011 including $897.1 million generated in the third quarter of 2011.

Share Repurchase Update

During the quarter, Gilead repurchased and retired a total of $883.6 million or 22.4 million shares of common stock. The company has completed its May 2010 $5.00 billion share repurchase program, which retired a total of 135.5 million common shares at an average price of $36.89 per share, and commenced its January 2011 three-year $5.00 billion share repurchase program. Since January 2010, Gilead repurchased and retired $6.18 billion or 164.2 million common shares or 18 percent of the company’s common stock outstanding at December 31, 2009.

Corporate Highlights

In July, Gilead announced an expansion of its access initiatives for its antiretrovirals in resource-limited countries. The company established new licensing terms with four India-based drug manufacturers – Hetero Drugs Ltd., Matrix Laboratories Ltd., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. – for three of its late-stage HIV pipeline products. In addition, Gilead became the first pharmaceutical company to enter a licensing agreement with the Medicines Patent Pool Foundation.

In August, Gilead announced the purchase of a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group. This transaction was completed in September 2011. Initially, Gilead will use the facility for the process development and manufacture of its investigational monoclonal antibody candidates.

Also in August, Gilead announced that it had resolved all outstanding issues raised in a Warning Letter issued by the U.S. FDA in September 2010 related to its San Dimas, California manufacturing facility.

Product and Pipeline Update

Antiviral Franchise

In July, Gilead announced Phase 3 clinical trial results from the pivotal Study 145 showing that its investigational antiretroviral elvitegravir, a novel oral integrase inhibitor being evaluated for the treatment of HIV-1 infection, was non-inferior to the integrase inhibitor raltegravir after 48 weeks of therapy in treatment-experienced patients. The data were presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome, Italy.

In August, Gilead announced that the FDA had approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

Also in August, Gilead announced that a Phase 3 clinical trial (Study 102) of its investigational fixed-dose, single-tablet "Quad” regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to Atripla.

In September, Gilead announced that the second pivotal Phase 3 clinical trial (Study 103) of the "Quad” in treatment-naïve HIV-1 infected patients met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada. Upon this announcement, Gilead updated its timelines for filing for U.S. regulatory approval to take place prior to the end of this year.

Also in September, Gilead announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, had adopted a positive opinion on the company’s Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera^®, launched first as Complera in the United States and is a combination of Gilead’s Truvada and Tibotec Pharmaceuticals’ non-nucleoside reverse transcriptase inhibitor Edurant^® (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in antiretroviral-naïve adults with a viral load less than or equal to 100,000 HIV-1 RNA copies/mL.

Conference Call

At 5:00 p.m. Eastern Time today, Gilead’s management will host a conference call and a simultaneous webcast to discuss results from its third quarter 2011 as well as provide a general business update. To access the webcast live via the internet, please connect to the company’s website at www.gilead.com 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-866-730-5765 (U.S.) or 1-857-350-1589 (international) and dial the participant passcode 52967950 to access the call.

A replay of the webcast will be archived on the company’s website for one year, and a phone replay will be available approximately two hours following the call through October 30, 2011. To access the phone replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 50031971.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

Non-GAAP Financial Information

Gilead has presented certain financial information in accordance with GAAP and also on a non-GAAP basis for the third quarter of 2011 and 2010. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under U.S. GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on page 7.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead’s ability to achieve its anticipated full year 2011 financial results, including the possibility that its full year 2011 guidance may be revised at a later date; Gilead’s ability to sustain growth in revenues for its antiviral, cardiovascular and respiratory franchises; unpredictable variability of Tamiflu royalties and the strong relationship between this royalty revenue and global pandemic planning and supply; the availability of funding for state AIDS Drug Assistance Programs (ADAPs) and their ability to purchase at levels to support the number of patients that rely on ADAPs; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead’s earnings; Gilead’s ability to submit New Drug Applications for new product candidates in the timelines currently anticipated, including for elvitegravir and cobicistat; Gilead’s ability to receive regulatory approvals in a timely manner or at all, for new and current products, including the Quad; Gilead’s ability to successfully commercialize its products, including the risk that physicians may not see advantages of Complera over other therapies and may therefore be reluctant to prescribe the product; Gilead’s ability to successfully develop its respiratory, cardiovascular and oncology franchises; safety and efficacy data from clinical studies may not warrant further development of Gilead’s product candidates; initiating and completing clinical trials may take longer or cost more than expected; the potential for additional austerity measures in European countries that may increase the amount of discount required on Gilead’s products; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead’s future revenues and pre-tax earnings; Gilead’s ability to complete the $5.00 billion share repurchase program due to changes in its stock price, corporate or other market conditions; and other risks identified from time to time in Gilead’s reports filed with the U.S. Securities and Exchange Commission. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market-specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words "may,” "will,” "would,” "could,” "should,” "might,” "believes,” "estimates,” "projects,” "potential,” "expects,” "plans,” "anticipates,” "intends,” "continues,” "forecast,” "designed,” "goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 and other subsequent disclosure documents filed with the Securities and Exchange Commission and press releases. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Truvada, Viread, Hepsera, Complera, Emtriva, AmBisome, Letairis, Cayston, and Ranexa are registered trademarks of Gilead Sciences, Inc.

Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.

Tamiflu is a registered trademark of F. Hoffmann-La Roche Ltd.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(in thousands, except per share amounts)
				Three Months Ended									Nine Months Ended
				September 30,									September 30,
				2011				2010					2011				2010
Revenues:
	Product sales			$	2,065,859			$	1,865,559				$	5,969,025			$	5,459,683
	Royalty, contract and other revenues				55,801				72,097					215,982				491,050
Total revenues					2,121,660				1,937,656					6,185,007				5,950,733
Costs and expenses:
	Cost of goods sold				531,989				477,584					1,539,963				1,373,539
	Research and development				290,066				230,440					826,915				680,170
	Selling, general and administrative				295,927				250,559					895,764				764,183
Total costs and expenses					1,117,982				958,583					3,262,642				2,817,892
Income from operations					1,003,678				979,073					2,922,365				3,132,841
Interest and other income, net					14,406				15,593					40,216				49,523
Interest expense					(43,097	)			(33,620	)				(130,420	)			(68,339	)
Income before provision for income taxes					974,987				961,046					2,832,161				3,114,025
Provision for income taxes					237,449				258,883					704,861				850,641
Net income					737,538				702,163					2,127,300				2,263,384
Net loss attributable to noncontrolling interest					3,586				2,713					11,192				8,454
Net income attributable to Gilead				$	741,124			$	704,876				$	2,138,492			$	2,271,838
Net income per share attributable to Gilead common stockholders - basic				$	0.97			$	0.85				$	2.72			$	2.61
Net income per share attributable to Gilead common stockholders - diluted				$	0.95			$	0.83				$	2.66			$	2.55
Shares used in per share calculation - basic					767,033				833,006					787,272				871,887
Shares used in per share calculation - diluted					781,312				847,228					802,762				890,216

GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)
(in thousands, except percentages and per share amounts)
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2011				2010				2011				2010
Cost of goods sold reconciliation:
GAAP cost of goods sold			$	531,989			$	477,584			$	1,539,963			$	1,373,539
	Acquisition-related amortization of inventory mark-up			-				-				-				(7,020	)
	Acquisition-related amortization of purchased intangibles			(17,407	)			(14,981	)			(52,222	)			(44,946	)
	Stock-based compensation expenses			(2,234	)			(2,728	)			(7,765	)			(8,548	)
Non-GAAP cost of goods sold			$	512,348			$	459,875			$	1,479,976			$	1,313,025
Product gross margin reconciliation:
GAAP product gross margin				74.3	%			74.4	%			74.3	%			74.9	%
	Acquisition-related amortization of inventory mark-up			-				-				-				0.1	%
	Acquisition-related amortization of purchased intangibles			0.8	%			0.8	%			0.9	%			0.8	%
	Stock-based compensation expenses			0.1	%			0.1	%			0.1	%			0.2	%
Non-GAAP product gross margin (1)				75.3	%			75.4	%			75.3	%			76.0	%
Research and development expenses reconciliation:
GAAP research and development expenses			$	290,066			$	230,440			$	826,915			$	680,170
	Acquisition-related transaction costs			-				-				(446	)			-
	Acquisition-related remeasurement of contingent consideration			(1,616	)			-				(1,198	)			-
	Restructuring expenses			(806	)			(6,315	)			(1,360	)			(10,545	)
	Stock-based compensation expenses			(18,389	)			(20,946	)			(54,529	)			(62,536	)
Non-GAAP research and development expenses			$	269,255			$	203,179			$	769,382			$	607,089
Selling, general and administrative expenses reconciliation:
GAAP selling, general and administrative expenses			$	295,927			$	250,559			$	895,764			$	764,183
	Acquisition-related transaction costs			(535	)			(387	)			(1,278	)			(387	)
	Restructuring expenses			(4,388	)			(1,413	)			(6,054	)			(14,903	)
	Stock-based compensation expenses			(25,897	)			(28,128	)			(83,821	)			(75,606	)
Non-GAAP selling, general and administrative expenses			$	265,107			$	220,631			$	804,611			$	673,287
Operating margin reconciliation:
GAAP operating margin				47.3	%			50.5	%			47.2	%			52.6	%
	Acquisition-related transaction costs			0.0	%			0.0	%			0.0	%			0.0	%
	Acquisition-related amortization of inventory mark-up			-				-				-				0.1	%
	Acquisition-related amortization of purchased intangibles			0.8	%			0.8	%			0.8	%			0.8	%
	Acquisition-related remeasurement of contingent consideration			0.1	%			-				0.0	%			-
	Restructuring expenses			0.2	%			0.4	%			0.1	%			0.4	%
	Stock-based compensation expenses			2.2	%			2.7	%			2.4	%			2.5	%
Non-GAAP operating margin (1)				50.7	%			54.4	%			50.6	%			56.4	%
Net income attributable to Gilead reconciliation:
GAAP net income attributable to Gilead			$	741,124			$	704,876			$	2,138,492			$	2,271,838
	Acquisition-related transaction costs			535				388				1,724				388
	Acquisition-related amortization of inventory mark-up			-				-				-				5,090
	Acquisition-related amortization of purchased intangibles			13,172				10,951				39,225				32,680
	Acquisition-related remeasurement of contingent consideration			1,213				-				900				-
	Restructuring expenses			3,908				5,639				5,569				18,488
	Stock-based compensation expenses			35,221				37,812				109,750				106,620
Non-GAAP net income attributable to Gilead			$	795,173			$	759,666			$	2,295,660			$	2,435,104
Diluted earnings per share reconciliation:
GAAP diluted earnings per share			$	0.95			$	0.83			$	2.66			$	2.55
	Acquisition-related transaction costs			0.00				0.00				0.00				0.00
	Acquisition-related amortization of inventory mark-up			-				-				-				0.01
	Acquisition-related amortization of purchased intangibles			0.02				0.01				0.05				0.04
	Acquisition-related remeasurement of contingent consideration			0.00				-				0.00				-
	Restructuring expenses			0.01				0.01				0.01				0.02
	Stock-based compensation expenses			0.05				0.04				0.14				0.12
Non-GAAP diluted earnings per share (1)			$	1.02			$	0.90			$	2.87			$	2.74
Shares used in per share calculation (diluted) reconciliation:
GAAP shares used in per share calculation (diluted)				781,312				847,228				802,762				890,216
	Share impact of current stock-based compensation guidance			(2,096	)			(2,208	)			(2,007	)			(1,621	)
Non-GAAP shares used in per share calculation (diluted)				779,216				845,020				800,755				888,595
Non-GAAP adjustment summary:
	Cost of goods sold adjustments		$	19,641			$	17,709			$	59,987			$	60,514
	Research and development expenses adjustments			20,811				27,261				57,533				73,081
	Selling, general and administrative expenses adjustments			30,820				29,928				91,153				90,896
Total non-GAAP adjustments before tax				71,272				74,898				208,673				224,491
Income tax effect				(17,223	)			(20,108	)			(51,505	)			(61,225	)
Total non-GAAP adjustments after tax			$	54,049			$	54,790			$	157,168			$	163,266
Note:
(1) Amounts may not sum due to rounding

GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
			September 30,			December 31,
			2011			2010
			(unaudited)			(Note 1)
Cash, cash equivalents and marketable securities			$	5,482,116		$	5,318,071
Accounts receivable, net				1,867,092			1,621,966
Inventories				1,337,751			1,203,809
Property, plant and equipment, net				761,190			701,235
Intangible assets				2,111,003			1,425,592
Other assets				1,080,746			1,321,957
	Total assets		$	12,639,898		$	11,592,630
Current liabilities			$	2,224,431		$	2,464,950
Long-term liabilities				4,182,261			3,005,843
Stockholders’ equity (Note 2)				6,233,206			6,121,837
	Total liabilities and stockholders’ equity		$	12,639,898		$	11,592,630
Notes:
(1)	Derived from audited consolidated financial statements at that date.
(2)	As of September 30, 2011, there were 756,094 shares of common stock issued and outstanding.

GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
(in thousands)
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2011			2010			2011			2010
Antiviral products:
	Atripla – U.S.		$	501,576		$	491,645		$	1,474,580		$	1,414,365
	Atripla – Europe			254,957			222,727			775,167			661,424
	Atripla – Other International			38,166			28,320			111,456			75,579
				794,699			742,692			2,361,203			2,151,368
	Truvada – U.S.			357,660			325,545			1,011,837			969,884
	Truvada – Europe			319,149			292,028			940,312			867,929
	Truvada – Other International			67,918			51,168			176,990			130,409
				744,727			668,741			2,129,139			1,968,222
	Viread – U.S.			87,712			82,431			240,420			239,225
	Viread – Europe			82,927			72,489			245,062			216,636
	Viread – Other International			22,248			29,343			61,517			85,260
				192,887			184,263			546,999			541,121
	Hepsera – U.S.			14,170			19,055			42,809			60,090
	Hepsera – Europe			18,223			25,095			60,293			87,021
	Hepsera – Other International			3,238			3,369			9,281			9,866
				35,631			47,519			112,383			156,977
	Complera - U.S.			19,044			-			19,044			-
	Complera - Europe			-			-			-			-
	Complera - Other			-			-			-			-
				19,044			-			19,044			-
	Emtriva – U.S.			4,666			3,966			12,482			12,345
	Emtriva – Europe			1,772			1,657			5,162			5,216
	Emtriva – Other International			1,229			1,073			3,331			3,036
				7,667			6,696			20,975			20,597
Total Antiviral products – U.S.				984,828			922,642			2,801,172			2,695,909
Total Antiviral products – Europe				677,028			613,996			2,025,996			1,838,226
Total Antiviral products – Other International				132,799			113,273			362,575			304,150
				1,794,655			1,649,911			5,189,743			4,838,285
AmBisome				82,241			75,132			249,372			230,355
Letairis				78,954			60,446			214,765			176,293
Ranexa				81,983			60,312			236,353			172,015
Other products				28,026			19,758			78,792			42,735
				271,204			215,648			779,282			621,398
Total product sales			$	2,065,859		$	1,865,559		$	5,969,025		$	5,459,683